Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3067831 | 1.00 | PDE4A (0.59) | PDE4ALMNATDP1L3MBTL1USP2 | |
| SCHEMBL19952978 | 1.00 | PDE4A (0.59) | PDE4ALMNATDP1L3MBTL1USP2 | |
| SCHEMBL288150 | 1.00 | PDE4A (0.59) | PDE4ALMNATDP1L3MBTL1USP2 | |
| SCHEMBL258100 | 1.00 | PDE4A (0.59) | PDE4ALMNATDP1L3MBTL1USP2 | |
| SCHEMBL29563836 | 1.00 | PDE4A (0.59) | PDE4ALMNATDP1L3MBTL1USP2 | |
| SCHEMBL2135451 | 0.92 | PDE4A (0.55) | PDE4ALMNATDP1L3MBTL1USP2 | |
| SCHEMBL887710 | 0.92 | PDE4A (0.55) | PDE4ALMNATDP1L3MBTL1USP2 | |
| SCHEMBL3764484 | 0.82 | PDE4A (0.44) | PDE4ALMNATDP1L3MBTL1USP2 | |
| SCHEMBL14940504 | 0.82 | PDE4A (0.44) | PDE4ALMNATDP1L3MBTL1USP2 | |
| SCHEMBL677609 | 0.82 | PDE4A (0.44) | PDE4ALMNATDP1L3MBTL1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250144172-A1 | ANTI-FIBROTIC SIALIDASE INHIBITOR COMPOUNDS AND METHODS OF USE | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2025-05-08 | — | — | US | disclosed |
| EP-3509579-A1 | ANTI-FIBROTIC SIALIDASE INHIBITOR COMPOUNDS AND METHODS OF USE | The Texas A&M University System (US) | 2019-07-17 | — | — | EP | disclosed |
| US-20190201485-A1 | ANTI-FIBROTIC SIALIDASE INHIBITOR COMPOUNDS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-07-04 | — | — | US | disclosed |
| WO-2018049003-A1 | ANTI-FIBROTIC SIALIDASE INHIBITOR COMPOUNDS AND METHODS OF USE | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2018-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250144172-A1 | ANTI-FIBROTIC SIALIDASE INHIBITOR COMPOUNDS AND METHODS OF USE | MMP1, SERPINB1, MMP8 | PDE4A 1380/4885LMNA 1114/4885TDP1 1713/4885 |
| US-20190201485-A1 | ANTI-FIBROTIC SIALIDASE INHIBITOR COMPOUNDS AND METHODS OF USE | MMP1, SERPINB1, MMP8 | PDE4A 1380/4885LMNA 1114/4885TDP1 1713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.